Anti-inflammatory and gut microbiota-modulating effects of a novel mannan from Scilla scilloides on DSS-induced colitis in mice

Researchers isolated and characterized a novel polysaccharide called SCSP-W from Scilla scilloides, a plant used in traditional medicine, and tested whether it could reduce gut inflammation in a mouse model of colitis. SCSP-W turned out to be a mannan — a type of sugar polymer built mainly from mannose — with a precisely mapped molecular structure confirmed by advanced spectroscopic techniques. When given to mice with chemically induced colitis (using dextran sodium sulfate, DSS), SCSP-W reduced key signs of disease: it lowered pro-inflammatory signaling molecules, strengthened the intestinal barrier, and shifted the gut microbial community toward more beneficial species. Notably, the compound appeared to act like a prebiotic, selectively feeding or supporting bacteria such as Lactobacillus that are associated with gut health. The study suggests SCSP-W hits several disease-relevant targets at once — inflammation, barrier integrity, and microbial balance — which is an unusual combination for a single plant-derived compound. These findings position SCSP-W as a candidate ingredient for functional foods or pharmaceutical development aimed at inflammatory bowel disease (IBD). Because this is an early-stage animal study, human relevance remains to be established.

• SCSP-W is a mannan polysaccharide composed predominantly of mannose (66.7 mol%), with galactose (18.1%), rhamnose (6.1%), arabinose (6.1%), and galacturonic acid (3%), as confirmed by NMR spectroscopy and methylation analysis.
• In DSS-induced colitis mice, SCSP-W significantly reduced pro-inflammatory cytokines TNF-α, IL-6, and IL-17, while increasing the anti-inflammatory cytokine IL-10, indicating bidirectional immunomodulation.
• SCSP-W restored expression of intestinal barrier-associated proteins compromised by DSS treatment, suggesting a direct protective effect on mucosal integrity.
• Treatment restored the relative abundance of beneficial gut bacteria including Lactobacillus, Spirochaeta, and Desulfovibrio, consistent with a prebiotic-like mechanism of action.
• The multi-targeted profile — simultaneously addressing inflammation, barrier function, and microbiota composition — was observed within a single DSS-colitis intervention, which the authors highlight as therapeutically distinctive.

This was a preclinical in vivo study using a DSS-induced acute colitis mouse model, a standard experimental system for investigating IBD-relevant mechanisms. Mice received SCSP-W orally; colonic tissue and fecal/microbiota samples were subsequently analyzed for inflammatory markers (cytokines by ELISA or similar), tight-junction/barrier proteins (likely by Western blot or immunohistochemistry), and gut microbial community composition (likely 16S rRNA sequencing). Structural characterization of the polysaccharide was performed prior to animal experiments using monosaccharide composition analysis, NMR spectroscopy, and methylation analysis. Specific group sizes, exact dosing regimens, and intervention duration are not reported in the abstract.

As an animal study, SCSP-W's efficacy, optimal dosing, bioavailability, and safety profile in humans are entirely unknown, and DSS-colitis does not fully recapitulate the immunological complexity of human IBD subtypes such as Crohn's disease or ulcerative colitis. The abstract does not disclose which specific barrier proteins were measured, the magnitude of microbial shifts (e.g., fold-change in Lactobacillus), or whether germ-free or antibiotic-depleted mouse experiments were performed to confirm that microbiota changes are mechanistically required — not merely correlative. The prebiotic-like classification is inferential; direct fermentation studies or metabolomic profiling of short-chain fatty acid production would be needed to confirm this mechanism. A logical next step would be human gut organoid or ex vivo colonoid experiments, followed by a Phase I safety trial, to begin bridging the translational gap.

This study parallels [§120], which also examines how microbiota modulation — in that case via Eubacterium rectale and glutamine metabolism — mitigates DSS-induced colitis in mice, reinforcing the broader principle that reshaping microbial communities can be a primary therapeutic lever in experimental IBD. The findings extend the mechanistic framework articulated in [§150], an editorial on gut microbiota in immune-mediated inflammatory disease, by providing a concrete single-compound example of how a dietary polysaccharide can simultaneously target cytokine networks and microbial ecology. The work also parallels [§119], where Emapunil suppresses macrophage pyroptosis in ulcerative colitis, illustrating that anti-colitis interventions in the current literature converge on inflammation suppression through mechanistically distinct routes — pharmacological pathway blockade versus prebiotic microbiota remodeling. Additionally, it parallels [§146], which shows intermittent fasting alleviates ulcerative colitis partly through macrophage reprogramming and lipid mediators, underscoring that both dietary-composition and dietary-pattern interventions can normalize gut immune tone, and inviting comparison of the depth and durability of their respective microbiota effects.

• Eubacterium rectale Mitigates Inflammatory Bowel Disease via Modulation of Glutamine Metabolism Through the GLS2 and NF-κB Pathway
  Both studies use DSS-colitis mice and microbiota modulation as the therapeutic axis, but Article 120 anchors its mechanism in a specific bacterium (Eubacterium rectale) and glutamine metabolism, making it a useful contrast to SCSP-W's broader polysaccharide-driven microbial shift.
• Emapunil attenuates ulcerative colitis by suppressing Z-DNA binding protein 1 driven pyroptosis and pro-inflammatory polarization in macrophages
  Emapunil targets macrophage pyroptosis via ZBP1 in the same DSS-colitis model, providing a direct mechanistic counterpoint — pharmacological immune-cell pathway blockade versus prebiotic-style microbiota remodeling — for readers assessing which upstream target is more therapeutically actionable.
• Intermittent fasting alleviates ulcerative colitis via lithocholic acid-mediated macrophage reprogramming
  Intermittent fasting alleviates ulcerative colitis through lithocholic acid-mediated macrophage reprogramming, offering a dietary-pattern comparator to SCSP-W's dietary-component approach and raising the question of whether the two strategies produce additive or overlapping microbiota and inflammatory benefits.
• Editorial: The role of gut microbiota in immune-related inflammatory diseases
  This editorial synthesizes the field-level evidence for gut microbiota in immune-related inflammatory diseases and provides the conceptual scaffolding within which SCSP-W's prebiotic-like findings should be interpreted and critiqued.
• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Saccharomyces boulardii CNCM I-745 is a well-characterized intervention studied for intestinal barrier function, making it a useful benchmark for evaluating the barrier-restoration claims made for SCSP-W, particularly given the yeast's established clinical evidence base that the mannan currently lacks.